Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14186809 | 0.90 | MAPT (0.41) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL365903 | 0.90 | MAPT (0.41) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL1418414 | 0.90 | PDGFRB (0.42) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL522786 | 0.87 | CA12 (0.47) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL17185155 | 0.86 | CA12 (0.46) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL20470613 | 0.86 | PDGFRB (0.42) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL23703855 | 0.85 | KDM4E (0.47) | MAPTKDM4EGAALMNAPOLB | |
| SCHEMBL850400 | 0.85 | SOS1 (0.44) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL19175223 | 0.85 | KDM4E (0.47) | MAPTKDM4EGAALMNAPOLB | |
| SCHEMBL3411975 | 0.85 | SOS1 (0.48) | MAPTCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227337-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AJINOMOTO CO., INC. (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| WO-2018052772-A1 | HETEROARYL CARBOXAMIDE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130754-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | MAPT 4318/4885CA12 4670/4885CA1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.